Hormone Replacement Therapy Market size is estimated to cross USD 57 Billion by the end of 2033, growing at a CAGR of 8% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of hormone replacement therapy was over USD 32 Billion. The growth of the market is primarily attributed to the higher prevalence of chronic conditions such as hypogonadism in adult males across the globe. For instance, globally, hypogonadal males account for approximately 42% of men over the age of 45 and 55% of men in their 80s. Moreover, rising awareness regarding the post- menopausal issues among women is another major factor which is driving the growth of the market over the projected forecast period.
Global hormone replacement therapy market trends such as, skyrocketing investment by the government in the R&D of new medical technology and the growing prevalence of high blood pressure & hypertension are projected to influence the growth of the market positively over the forecast period. For instance, it is estimated that in every 4 adults, 1 of them aged between 20 to 45 suffers from high blood pressure worldwide. Additionally, in 2018, around 45% of the global population was projected to live with hypertension. Hence, all these factors are anticipated to propel the growth of the market over the forecast period.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
8% |
|
Base Year Market Size (2022) |
USD 32 Billion |
|
Forecast Year Market Size (2033) |
USD 57 Billion |
|
Regional Scope |
|
Administration Route (Parenteral, Transdermal, Oral)
The global hormone replacement therapy market is segmented and analyzed for demand and supply by administration route into parenteral, transdermal, and oral, out of which, the transdermal segment is projected to witness noteworthy growth over the forecast period. The growth of the segment is accounted to the rising demand for transdermal drug delivery and ease of application. For instance, it is estimated that over 1 million transdermal patches are produced worldwide every year.
Our in-depth analysis of the global market includes the following segments:
|
By Replacement Therapy |
|
|
By Administration Route |
|
|
By Indication |
|
North America Market Forecast
The North America hormone replacement therapy market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market is ascribed to the significant growth in the geriatric population along with the significant presence of a well-structured healthcare infrastructure. World Bank released a set of data showing the geriatric population in the United States reached 56,545,938 in 2021. Moreover, rising cases of cancer and spiking penetration of major key players of the market in the region are further expected to hike the growth of the market over the forecast period.
Orion Pharma AB to acquire the clearance for darolutamide indication in the combination with docetaxel from U.S. Food and Drug Administration (FDA). The product is developed for the treatment of metastatic hormone-sensitive prostate cancer shortly known as (mHSPC).
Genentech, Inc. to release positive results from the Phase III SKYSCRAPER-01 study. The study was being conducted to monitor the anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) vs Tecentriq alone as an initial (first-line) to find the cure for people living with advanced or metastatic non-small cell lung cancer (NSCLC).
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?